Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Heitmeier

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Thrombosis Research|May 1, 2016
Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatranPeter Ellinghaus, Elisabeth Perzborn, Peter Hauenschild, et al.
Critical Care (London, England)|March 15, 2017
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsisHerbert Schöchl, Martijn van Griensven, Stefan Heitmeier, et al.
Thrombosis and Haemostasis|May 3, 2013
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primatesElisabeth Perzborn, András Gruber, Hanna Tinel, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 27, 2019
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IXMayken Visser, René van Oerle, Hugo Ten Cate, et al.
Anesthesiology|August 9, 2021
Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal ModelFarahnaz Rayatdoost, Till Braunschweig, Benjamin Maron, et al.
Thrombosis and Haemostasis|November 6, 2009
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?Volker Laux, Elisabeth Perzborn, Stefan Heitmeier, et al.
Journal of Thrombosis and Haemostasis : JTH|March 15, 2022
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIaStefan Heitmeier, Mayken Visser, Adrian Tersteegen, et al.
Thrombosis Research|October 14, 2016
Platelet function in baboons and humans - A comparative study of whole blood using impedance platelet aggregometry (Multiplate®)Martin Ponschab, Martijn van Griensven, Stefan Heitmeier, et al.
Frontiers in Immunology|May 2, 2025
Recombinant chymase inhibits fibrinolysis induced by endogenous plasmin in clotted human bloodLaurence Vincent, Catherine Lapointe, Patrick P McDonald, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 26, 2023
Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in HumansIsabel Piel, Anna Engelen, Dieter Lang, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Thrombosis Research|May 1, 2016
Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatranPeter Ellinghaus, Elisabeth Perzborn, Peter Hauenschild, et al.
Critical Care (London, England)|March 15, 2017
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsisHerbert Schöchl, Martijn van Griensven, Stefan Heitmeier, et al.
Thrombosis and Haemostasis|May 3, 2013
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primatesElisabeth Perzborn, András Gruber, Hanna Tinel, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 27, 2019
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IXMayken Visser, René van Oerle, Hugo Ten Cate, et al.
Anesthesiology|August 9, 2021
Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal ModelFarahnaz Rayatdoost, Till Braunschweig, Benjamin Maron, et al.
Thrombosis and Haemostasis|November 6, 2009
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?Volker Laux, Elisabeth Perzborn, Stefan Heitmeier, et al.
Journal of Thrombosis and Haemostasis : JTH|March 15, 2022
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIaStefan Heitmeier, Mayken Visser, Adrian Tersteegen, et al.
Thrombosis Research|October 14, 2016
Platelet function in baboons and humans - A comparative study of whole blood using impedance platelet aggregometry (Multiplate®)Martin Ponschab, Martijn van Griensven, Stefan Heitmeier, et al.
Frontiers in Immunology|May 2, 2025
Recombinant chymase inhibits fibrinolysis induced by endogenous plasmin in clotted human bloodLaurence Vincent, Catherine Lapointe, Patrick P McDonald, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 26, 2023
Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in HumansIsabel Piel, Anna Engelen, Dieter Lang, et al.
Pageof 5